COX-2-selective inhibitors in the treatment of arthritis

Thomas J. Schnitzer*, Marc C. Hochberg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations

Abstract

Therapy with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) has long been the cornerstone of pharmacologic management of patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Many patients with OA or RA, however, are at increased risk of developing clinically significant adverse events associated with NSAID therapy, particularly upper gastrointestinal (GI) complications including symptomatic and complicated ulcers. The introduction of cyclooxygenase (COX)-2-selective inhibitors (coxibs) represents a major advance in the pharmacologic approach to the signs and symptoms of arthritis. In addition to the first two members of this class, celecoxib and rofecoxib, other coxibs have been introduced or are in development (valdecoxib, etoricoxib). In numerous clinical trials, coxibs have been shown to be as effective as non-selective NSAIDs in relieving pain and inflammation associated with OA and RA, and notably, with a significantly lower risk of NSAID-type adverse events. The use of coxibs to treat OA and RA is recommended as first-line therapy when symptoms of pain and inflammation are present in patients vulnerable to potential NSAID-associated GI toxicity.

Original languageEnglish (US)
Pages (from-to)SI20-SI30
JournalCleveland Clinic journal of medicine
Volume69
Issue numberSUPPL. 1
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'COX-2-selective inhibitors in the treatment of arthritis'. Together they form a unique fingerprint.

Cite this